Subscribe to RSS

DOI: 10.1055/s-0045-1812850
Data-Driven Realism: Why Every Oncologist Must Analyze and Publish Their Clinical Outcomes
Authors
Funding None.

Introduction
Oncologists are at the front lines of cancer care. They navigate a complex landscape of rapidly changing treatments, technologies, and patient expectations. In this dynamic environment, it is essential for oncologists to carefully examine and share their clinical data. This practice is not just an academic task; it is vital for fostering a realistic understanding of cancer outcomes. It helps prevent undue influence from market-driven innovations and ensures optimal patient-centered care. Such care focuses on prevention and early intervention instead of resorting to last-minute technological fixes that can often be misleading.
Patient Consent
Patient consent is not required.
Publication History
Article published online:
30 October 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 
            References
- 1 Wilson BE, Booth CM. Real-world data: bridging the gap between clinical trials and practice. EClinicalMedicine 2024; 78 (78) 102915
- 2 Cheng AL, Kang YK, Chen Z. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (01) 25-34
- 3 Llovet JM, Ricci S, Mazzaferro V. et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (04) 378-390
- 4 Sanoff HK, Chang Y, Lund JL, O'Neil BH, Dusetzina SB. Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncologist 2016; 21 (09) 1113-1120
- 5 Templeton AJ, Vera-Badillo FE, Wang L. et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24 (12) 2972-2977
- 6 Tannock IF, de Wit R, Berry WR. et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15) 1502-1512
- 7 Bonner JA, Harari PM, Giralt J. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354 (06) 567-578
- 8 Albarmawi H, Cullen KJ, Mehra R, Onukwugha E, Goloubeva O. Cost-effectiveness of concurrent radiation with cetuximab or chemotherapy in older patients with oropharyngeal cancer. J Comp Eff Res 2022; 11 (08) 595-607
- 9 Stanbouly D, Philipone E, Morlandt AB, Kaleem A, Chuang SK, Patel N. Adverse events secondary to cetuximab therapy in head & neck cancer therapy and risk factors for serious outcomes. Oral Oncol 2022; 131: 105952
- 10 Krishnamurthy S, Ahmed I, Bhise R. et al. The dogma of cetuximab and radiotherapy in head and neck cancer - a dawn to dusk journey. Clin Transl Radiat Oncol 2022; 34: 75-81
- 11 Prakash G, Bakhshi S, Raina V. et al. Characteristics and pattern of mortality in cancer patients at a tertiary care oncology center: report of 259 cases. Asian Pac J Cancer Prev 2010; 11 (06) 1755-1759
- 12 Penninckx B, Van de Voorde WM, Casado A, Reed N, Moulin C, Karrasch M. A systemic review of toxic death in clinical oncology trials: an Achilles' heel in safety reporting revisited. Br J Cancer 2012; 107 (01) 1-6
- 13 Yang P, Zheng Y, Chen J. et al. Immediate risk of non-cancer deaths after a cancer diagnosis. BMC Cancer 2021; 21 (01) 963
- 14 Babu A, Noel Alexander F H, Muzumder S, Srikantia N, Udayashankar AH. Sepsis surveillance in patients with head-and-neck cancer undergoing chemo-radiation. Support Care Cancer 2024; 32 (11) 724
- 15 Khoja L, McGurk A, O'Hara C, Chow S, Hasan J. Mortality within 30 days following systemic anti-cancer therapy, a review of all cases over a 4 year period in a tertiary cancer centre. Eur J Cancer 2015; 51 (02) 233-240
- 16 Feliu J, Pinto A, Basterretxea L. et al. Development and validation of an early mortality risk score for older patients treated with chemotherapy for cancer. J Clin Med 2021; 10 (08) 1615
- 17 https://www.fda.gov/media/120060/download
 
     
      
         
      
    